| Group | # Patients, # eyes | Age (mean ± std dev (range)) | p-value | Visual Acuity in logMAR (mean ± std dev (range)) | p-value | Pseudophakic (n (%)) | p-value |
---|---|---|---|---|---|---|---|---|
MS | Healthy controls | 123, 200 | 48.5 ± 21.9 (19–92) |  | − 0.03 ± 0.14 (− 0.88 to 0.13) |  | 52 (26%) |  |
No History of Optic Neuritis | 14, 22 | 51.3 ± 11.9 (29–70) | 0.36 | − 0.04 ± 0.10 (− 0.30 to 0.00) | 0.22 | 2 (9%) | 0.17 | |
 + History of Optic Neuritis | 6, 9 | 44.1 ± 11.7 (30–61) | 0.31 | − 0.09 ± 0.16 (− 0.63 to 0.00) | 0.97 | 0 (0%) | 0.14 | |
AMD | Healthy controls (≥ 64 years) | 54, 73 | 72.5 ± 6.0 (64–92) |  | − 0.09 ± 0.17 (− 0.88 to 0.13) |  | 45 (62%) |  |
Early | 14, 23 | 75.6 ± 8.6 (64–94) | .12 | − 0.12 ± 0.12 (− 0.40 to 0.00) | 0.97 | 13 (57%) | 0.85 | |
Intermediate | 24, 37 | 79.1 ± 7.6 (67–93) |  < .01* | − 0.17 ± 0.16 (− 0.48 to 0.00) | 0.19 | 24 (65%) | 0.90 | |
Advanced | 6, 7 | 82.9 ± 8.7 (69–90) | 0.02* | − 0.31 ± 0.20 (− 0.60 to 0.10) | 0.08 | 4 (57%) | 0.99 | |
 | Neovascular | 7, 10 | 83.5 ± 6.3 (74–93) |  < .01* | − 0.30 ± 0.14 (− 0.48 to 0.10) |  < .01* | 8 (80%) | 0.43 |
ERM | Healthy controls (≥ 50 years) | 74, 103 | 72.3 ± 10.4 (50–94) |  | − 0.18 ± 0.15 (− 0.54 to 0.00) |  | 52 (51%) |  |
Stage 1 | 26, 30 | 74.7 ± 10.8 (56–94) |  < .01* | − 0.14 ± 0.14 (− 0.50 to 0.00) | 0.33 | 20 (67%) | 0.17 | |
Stage 2 | 17, 20 | 71.0 ± 10.2 (50–87) | 0.24 | − 0.19 ± 0.17 (− 0.54 to 0.00) | 0.08 | 13 (65%) | 0.34 | |
Stage 3 | 6, 7 | 66.0 ± 6.5 (56–74) | 0.45 | − 0.28 ± 0.13 (− 0.54 to 0.18) | 0.05* | 4 (57%) | 0.99 | |
RVO | Total | 11, 11 | 68.0 ± 10.7 (51–81) | NA | − 0.26 ± 0.16 (− 0.48 to 0.00) | NA | 5 (46%) | NA |